BRPI0415695A - agente imunoterápico útil para o tratamento combinado de tuberculose em associação com outras drogas - Google Patents

agente imunoterápico útil para o tratamento combinado de tuberculose em associação com outras drogas

Info

Publication number
BRPI0415695A
BRPI0415695A BRPI0415695-1A BRPI0415695A BRPI0415695A BR PI0415695 A BRPI0415695 A BR PI0415695A BR PI0415695 A BRPI0415695 A BR PI0415695A BR PI0415695 A BRPI0415695 A BR PI0415695A
Authority
BR
Brazil
Prior art keywords
tuberculosis
drugs
combined treatment
immunotherapeutic agent
combination
Prior art date
Application number
BRPI0415695-1A
Other languages
English (en)
Inventor
Pere Joan Cardona Iglesias
Original Assignee
Archivel Farma Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archivel Farma Sl filed Critical Archivel Farma Sl
Publication of BRPI0415695A publication Critical patent/BRPI0415695A/pt
Publication of BRPI0415695A8 publication Critical patent/BRPI0415695A8/pt
Publication of BRPI0415695B1 publication Critical patent/BRPI0415695B1/pt
Publication of BRPI0415695B8 publication Critical patent/BRPI0415695B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"AGENTE IMUNOTERáPICO úTIL PARA O TRATAMENTO COMBINADO DE TUBERCULOSE EM ASSOCIAçãO COM OUTRAS DROGAS". Refere-se a presente invenção a um agente imunoterápico baseado em fragmentos das paredes celulares de linhagens virulentas de Mycobacterium tuberculosis, a um método para a obtenção deste agente imunoterápico, às formulações farmacêuticas que o contém e a sua utilização para a preparação de uma droga para o tratamento combinado de tuberculose em associação com outras drogas.
BRPI0415695A 2003-10-31 2004-10-29 agente imunoterápico útil para o tratamento combinado de tuberculose em associação com outras drogas BRPI0415695B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200302551A ES2231037B1 (es) 2003-10-31 2003-10-31 Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
EPP200302551 2003-10-31
PCT/ES2004/000482 WO2005042013A1 (es) 2003-10-31 2004-10-29 Agente immunoterápico útil para el tratamento combinado de la tuberculosis en associación con otros fármacos

Publications (4)

Publication Number Publication Date
BRPI0415695A true BRPI0415695A (pt) 2006-12-26
BRPI0415695A8 BRPI0415695A8 (pt) 2019-01-15
BRPI0415695B1 BRPI0415695B1 (pt) 2019-09-10
BRPI0415695B8 BRPI0415695B8 (pt) 2021-05-25

Family

ID=34530979

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415695A BRPI0415695B8 (pt) 2003-10-31 2004-10-29 agente imunoterápico útil para o tratamento combinado de tuberculose em associação com outras drogas

Country Status (20)

Country Link
US (1) US8246944B2 (pt)
EP (1) EP1690549B1 (pt)
JP (1) JP4998988B2 (pt)
KR (1) KR101146469B1 (pt)
CN (1) CN100490894C (pt)
AT (1) ATE428442T1 (pt)
AU (1) AU2004285305B2 (pt)
BR (1) BRPI0415695B8 (pt)
CA (1) CA2543659C (pt)
DE (1) DE602004020663D1 (pt)
DK (1) DK1690549T3 (pt)
ES (2) ES2231037B1 (pt)
IL (1) IL175030A (pt)
MA (1) MA28121A1 (pt)
NZ (1) NZ546715A (pt)
PL (1) PL1690549T3 (pt)
PT (1) PT1690549E (pt)
RU (1) RU2341287C2 (pt)
WO (1) WO2005042013A1 (pt)
ZA (1) ZA200604234B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2231037B1 (es) 2003-10-31 2005-12-16 Archivel Technologies, Sl Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
WO2007132790A1 (ja) * 2006-05-12 2007-11-22 National University Corporation Hokkaido University 細菌菌体成分を含む脂質膜を有するリポソーム
ES2307402B1 (es) 2006-10-30 2009-09-30 Archivel Farma, S.L. Vacuna profilactica contra la tuberculosis.
ES2335177B1 (es) 2008-09-19 2011-02-28 Archivel Farma, S.L. Agente inmunoterapeutico apropiado para la profilaxis primaria de la tuberculosis.
BR112013017267B1 (pt) * 2011-01-04 2021-06-22 Archivel Farma, Sl Formulação de lipossomas, suspensão e composição farmacêutica
EP2471511A1 (en) 2011-01-04 2012-07-04 Archivel Farma, SL Liposome formulation suitable for treating or preventing tuberculosis
IN2014MN01594A (pt) 2012-01-12 2015-05-08 Archivel Farma Sl
ES2758400B2 (es) 2018-11-02 2021-01-20 Univ Granada Nanoparticulas biomimeticas mediadas por mamc
CN120456894A (zh) 2021-10-14 2025-08-08 爱琴韦尔制药公司 用于治疗活动性结核病的脂质体制剂
WO2025191183A1 (en) 2024-03-15 2025-09-18 Archivel Farma S.L. Liposome formulations for the treatment of cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3125598A1 (de) * 1981-06-30 1983-01-13 Mahle Gmbh, 7000 Stuttgart Einrichtung zur druckbeaufschlagung des presszylinders einer druckgiessmaschine
JPS59161320A (ja) * 1983-03-04 1984-09-12 Maruyama Chisato リポ多糖体およびその製造法
GB8404280D0 (en) 1984-02-17 1984-03-21 Stanford J L Biological preparations
JPS624701A (ja) * 1985-06-29 1987-01-10 Maruyama Chisato リポ多糖体及びその製造法
US4744984A (en) * 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US6641814B1 (en) * 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
US5785975A (en) * 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
US6284255B1 (en) 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6982085B2 (en) * 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
AU766093B2 (en) * 1998-10-08 2003-10-09 Statens Serum Institut Tuberculosis vaccine and diagnostic reagents based on antigens from the mycobacterium tuberculosis cell
RU2153354C1 (ru) * 1999-03-31 2000-07-27 Московский городской научно-практический центр борьбы с туберкулезом Вакцина против туберкулеза
EP1351699A4 (en) * 2000-12-08 2006-07-05 Ying Dr Zhang METHOD FOR IMPROVED DIAGNOSIS AND TREATMENT OF MYCOBACTERIAL INFECTIONS
CA2689741C (en) * 2001-01-08 2013-10-01 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services, Centers For Disea Latent human tuberculosis model, diagnostic antigens, and methods of use
US6670383B2 (en) * 2001-03-16 2003-12-30 Advanced Life Sciences, Inc. Pyranocoumarin compounds as a novel pharmacophore with anti-TB activity
US7393540B2 (en) 2001-07-04 2008-07-01 Health Protection Agency Mycobacterial antigens expressed during latency
WO2003018053A1 (en) 2001-08-22 2003-03-06 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Vaccine against mycobacterial-induced diseases
BR0307262A (pt) 2002-01-29 2006-12-19 Bakulesh Mafatlal Khamar método de prover profilaxia para tuberculose em indivìduos hiv positivos
ES2231037B1 (es) 2003-10-31 2005-12-16 Archivel Technologies, Sl Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
DE102004053141A1 (de) * 2004-11-03 2006-05-04 Schülke & Mayr GmbH Desinfektionsmittel mit verbesserter Wirksamkeit gegen Mykobakterien

Also Published As

Publication number Publication date
ZA200604234B (en) 2007-11-28
WO2005042013A1 (es) 2005-05-12
US8246944B2 (en) 2012-08-21
CN100490894C (zh) 2009-05-27
BRPI0415695A8 (pt) 2019-01-15
CA2543659C (en) 2012-04-17
DE602004020663D1 (de) 2009-05-28
ATE428442T1 (de) 2009-05-15
EP1690549A1 (en) 2006-08-16
ES2231037A1 (es) 2005-05-01
EP1690549B1 (en) 2009-04-15
RU2006118795A (ru) 2007-12-10
PT1690549E (pt) 2009-07-20
AU2004285305B2 (en) 2009-11-12
BRPI0415695B8 (pt) 2021-05-25
ES2231037B1 (es) 2005-12-16
KR20060126963A (ko) 2006-12-11
NZ546715A (en) 2008-05-30
DK1690549T3 (da) 2009-08-17
RU2341287C2 (ru) 2008-12-20
MA28121A1 (fr) 2006-08-01
KR101146469B1 (ko) 2012-05-21
CN1874785A (zh) 2006-12-06
PL1690549T3 (pl) 2010-01-29
HK1098362A1 (zh) 2007-07-20
JP2007509910A (ja) 2007-04-19
US20070269501A1 (en) 2007-11-22
JP4998988B2 (ja) 2012-08-15
IL175030A0 (en) 2006-08-20
CA2543659A1 (en) 2005-05-12
ES2325835T3 (es) 2009-09-21
AU2004285305A1 (en) 2005-05-12
IL175030A (en) 2012-02-29
BRPI0415695B1 (pt) 2019-09-10

Similar Documents

Publication Publication Date Title
BRPI0410503B8 (pt) composição tópica e uso da composição
BRPI0411505A (pt) uso de um composto, método para modular a resposta imune de um indivìduo, composição farmacêutica, vacina, complexo, e, kit para a captura de uma molécula biologicamente ativa
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
CY1114863T1 (el) Στερεο παρασκευασμα
BR9815255A (pt) Toxina de botulismo modificada, vacina oralcontra o botulismo, vacina oral contra umantìgeno selecionado e método para ministraroralmente um agente terapêutico a um animal
BRPI0414907A (pt) formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas
ES2109832T3 (es) Composicion dermatologica o farmaceutica, procedimiento de preparacion y utilizacion
AR019690A1 (es) Formulacion farmaceutica para aerosoles con dos o mas sustancias activas
BR0309390A (pt) Composição farmacêutica
BRPI0415695A8 (pt) agente imunoterápico útil para o tratamento combinado de tuberculose em associação com outras drogas
DK1383752T3 (da) Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser
BR0110091A (pt) Composições e processos para terapia e diagnóstico de câncer de mama
BR112013010829B8 (pt) Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
BR0311189A (pt) Composições farmacêuticas contendo polimorfo a de flibanserin
BRPI0414979A (pt) preparação sólida
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
BR0109502A (pt) Molécula de interesse farmacêutico, composição farmacêutica, vacina, método de diagnóstico in vitro de patologias associadas com a presença em um corpo de paciente de ligandos do mhc, pacote ou kit para execução de métodos de diagnóstico in vitro, utilizações de um ligando e de um ácido forte, e, processo de preparação e de estabilização de uma molécula de interesse farmacêutico
WO2004014367A3 (en) Use of an amyloid beta vaccination in combination with a selective cox-2 inhibitor for the treatment of alzheimer's disease
ATE521343T1 (de) Im mund zerfallende zusammensetzungen von rasagilin
BR0109747A (pt) Uso de 5-(2-pirazinil)-4-metil-1-2-ditiol-3-tiona (oltipraz) como um medicamento, composição farmacêutica para a prevenção e tratamento da progressão da fibrose hepática, uso de 5-(2-pirazinil)-4-metil-1, 2-ditiol-3-tiona e método para a prevenção e tratamento da progressão da fibrose e da cirrose hepática
BRPI0412430A (pt) polipeptìdeo agonista do receptor de zot e zonulina
BR0110512A (pt) Preparação para medir a taxa de esvaziamento gástrico
ES2156215T3 (es) Utilizacion de un conjugado en el tratamiento y/o diagnostico de enfermedades inflamatorias.
BR0316053A (pt) Uso de um polipeptìdeo de choque térmico e/ou uma sequência de ácido nucléico codificadora, e, método de aliviar a dor
GB2423927A (en) Combination Of Cicletanine And An Oral Antidiabetic And/Or Blood Lipid-Lowering Agent For Treating Diabetes And Metabolic Syndrome

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/09/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/09/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/10/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2853 DE 09-09-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.